Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Artios Launches With £25m To Study ‘PARP-esque’ DNA Damage Response Inhibitors

Executive Summary

Next generation DNA repair is the basis of new oncology-focused Artios Pharma, which has launched with a £25m series A round and a ‘PARP-esque’ discovery program.

You may also be interested in...



Finance Watch: Investments In Regenerative Therapies Surged In The Second Quarter

Global financings for cell and gene therapy and tissue engineering companies more than doubled in the second quarter; financings for the sector rose 79% in the first half of 2018. Also, Samumed leads recent venture funding deals with a $438m round.

Artios Pharma Hooks Novartis & Pfizer In Over-Subscribed £65M Series B Round

With DNA damage repair pathways attracting a lot of attention as potential targets against various cancers, three-year old Artios Pharma has raised £65 million in an over-subscribed Series B round to fund the clinical development of its pipeline through to 2023.

VC Roundup: Early-Stage Funding Slips Again In Third Quarter, Plus 15 New Financings

Early-stage venture capital funding continues to decline, but corporate VC dollars and other sources of cash are emerging to fund startups. Also, biopharma companies raised $436.3m in 15 recent financings.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1125347

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel